CD47 and neoplasm: In contrast, combining DNAJC13 knockout with anti-CD47 therapy significantly impaired tumor growth, suggesting that partial loss of CD47 primes tumors to respond more robustly to therapeutic blockade, possibly by enhancing the sensitivity of tumor cells to Fc-mediated effector mechanisms.